InfanDx AG i.L.

At the 2024 Annual General Meeting on May 13, 2024, InfanDx' shareholders unanimously decided to liquidate the Company.  This decision follows a recommendation by the Management and the Supervisory Board after a strategic review process.

The shareholders further appointed Dr.Achim Plum, previously Managing Director and CEO of InfanDx, as sole liquidator.

For more information see here.

For more information see here:
Corporate Presentation (pdf)
Leadership Management
InfanDx Team combines seasoned diagnostics industry leaders with high-potentials that are talented experts in their respective disciplines.

Supervisory Board

InfanDx Supervisory Board combines life science industry experts with serial entrepreneurs and investment professionals.

Scientific Advisory Board

Our distinguished Scientific Advisory Board provides us with access to unparalleled scientific and clinical expertise in neonatal diagnostics, metabolomics, and biostatistics - on a daily basis.
No items found.

Scientific Advisory

No items found.